Health-Related Quality of Life and disease-specific symptoms among Lymphoma and Multiple Myeloma survivors: A longitudinal PROFILES registry study. VITA-study

*Health-Related Quality of Life and disease-specific symptoms among Lymphoma and Multiple Myeloma survivors: A longitudinal PROFILES registry study. VITA-study* - VITA-study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52363

Enrollment

560

Registered

2021-09-22

Start date

2022-03-29

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphoma Multiple Myeloma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Patients diagnosed with either HL, NHL, CLL or MM - 18 years or older - Able to fill out questionnaires Dutch (in terms of language skills and cognitive abilities).

Exclusion criteria

Exclusion criteria: Patients with severe psychopathology or dementia, and patients in transition to terminal care will be excluded from the study. We will only have our questionnaire in Dutch, so patients who cannot read Dutch will be unable to complete the questionnaire.

Design outcomes

Primary

Measure	Time frame
Primary: HRQoL (EORTC QLQ-C30) and disease specific HRQoL/symptoms (EORTC QLQ-LYMPH32 or EORTC QLQ-MY20 + 2 single items from EORTC item library)	—

Secondary

Measure	Time frame
Secondary: neuropathy (single item from EORTC item library), sexual functioning/intimacy (5 single items from EORTC item library), anxiety and depressive symptoms (HADS), side effects (PRO-CTC-AE), personality (LOT-R and BFI), self-management (HEIQ), coping (SE7), health status (EQ-5D), therapy adherence (MARS) and health-care use.	—

Countries

Netherlands

Outcome results